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Background: The aim of this study was to assess the effect of local application of IGF-I on osseointegration of 
dental implants placed in osteoporotic bones.
Material and Methods: 16 rabbits were randomly distributed into two groups: eight animals were ovariectomized 
and fed a low-calcium diet for six weeks, in order to induce experimental osteoporosis, and the others were sham-
operated and fed a standard diet. A titanium implant was inserted into the tibiae in both groups. In half of the 
rabbits, 4 μg of IGF-I was applied into the ostectomy, prior to the implant insertion. A total of 32 implants were 
placed. Animals were sacrificed two weeks after surgery and decalcified samples were processed for Bone-To-
Implant Contact (BIC) and Bone Area Density (BAD) measurements. Analysis of variance (ANOVA) was used 
for statistical evaluation. P<0.05 was considered to be significant.
Results: Ovariectomy induced statistically significant lower BAD values (p=0.008) and a tendency towards lower 
BIC values when compared osteoporotic and healthy groups. The administration of 4 μg of IGF-I did not produce 
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Introduction
Bone is a dynamic tissue, that is continuously undergo-
ing resorption by osteoclasts and formation of new bone 
by osteoblasts. Bone tissue is renewed 10% per year; 
the amount of renovated cortical tissue is 3-5%, while 
the reposition of cancellous bone is 25% per year. Thus, 
total skeleton is renovated completely after10 years (1). 
Implant placement can be considered as an aggression 
towards the bone tissue that undergoes a process of re-
generation. An inflammatory response, hematoma, and 
a release of interleukins and growth factors constitute 
the cascade of events into the bone remodeling process 
(1). Among all factors, the growth hormone/insulin-like 
growth factor I (GH/IGF-I) axis is crucial for the regula-
tion of bone formation. GH and IGF-I play an important 
role in the acquisition of bone mass during adolescence 
as well as in the maintenance of bone mass during adult 
stage. GH/IGF-I axis deficiencies lead to osteoporosis 
and bone-loss disorders (2). IGF-I is a small peptide, 
with a similar structure to insulin, that acts as a sys-
temic and local regulator of skeletal growth. Circulating 
IGF-I is synthesized in the liver under GH control, and 
it is bound to IGF-binding protein-3 (IGFBP-3), among 
others (3). Circulating IGF-I mediates GH effects on 
longitudinal bone growth. Elsewhere, IGF-I is also syn-
thesized locally by osteoblasts in response to parathy-
roid hormone (PTH), mediating its anabolic effects on 
bone (4). IGF-I and II are the most abundant growth fac-
tors stored into the bone extracellular matrix (5).
IGF-I synthesis by the liver, is regulated not only by GH 
(3), but also depends on the individual nutritional sta-
tus. Thus, in anorexia nervosa, bone loss occurs, and it 
seems to be associated with a decrease in serum levels 
of IGF-I(6, 7).  
Osteoporosis is a skeletal systemic disease, character-
ized by a reduced bone mass, a deterioration in bone 
microarchitecture, and increased susceptibility for frac-
tures (8). It is estimated that over 200 million individu-
als suffer from osteoporosis in the world, constituting a 
major public health problem (9). Although the relation-
ship between skeletal and maxilla bone density has been 
controversial in the past, in the recent years it has been 
proven the influence of skeletal bone density on dental 
implant stability in patients with osteoporosis (10).
Animal studies have associated the presence of IGF-I 
and bone mass preservation. It has been proven that in 
knock out mice for IGF-I, osteopenia exists, confirm-
ing that IGF-I is an important factor in bone remodel-
Conclusions: Within the limitations of this experimental study, local administration of 4 μg of IGF-I was not able 
to induce any changes in the osseointegration process two weeks after surgery, neither in healthy rabbits nor in the 
osteoporotic group.
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ing (11). In addition, it is known that circulating IGF-I 
contributes to cortical mass maintenance, while local 
IGF-I participates in the integrity of cancellous bone 
(12). Moreover, low IGF-I serum levels are also related 
to reduced bone mass in rats, which is recovered with 
the administration of low doses of IGF-I (13).
Human studies to evaluate the effects of IGF-I on bone 
turnover are limited. A decline in GH/IGF-I axis in the 
elderly may contribute to the pathogenesis of osteopo-
rosis (14). In addition, it seems to exist a correlation be-
tween serum levels of IGF-I and bone mineral density 
(BMD) values in postmenopausal women (15), as well 
as reduced IGF-I levels are related with an increased 
risk for fractures (three times more frequently) (16), 
independently of other parameters such as BMD, age, 
duration of menopause, or body mass index (17).
Nowadays, therapeutic uses of IGF-I are limited to 
Laron Syndrome (severe primary IGF-I deficiency due 
to genetic GH resistance or insensitivity) (18, 19). This 
indication was approved by the FDA (Food and Drug 
Administration) in 2005, and by the EMA (European 
Medicament Agency) in 2007. However, several clinical 
trials have been carried out in order to assess the pos-
sible efficacy of recombinant IGF-I in other pathologies 
such as diabetes I and II (20), ALS (amyotrophic lateral 
sclerosis), Alzheimer, anorexia nervosa or osteoporosis. 
In patients with anorexia nervosa, IGF-I administra-
tion induced an increase in BMD values and markers 
of bone turnover in women with severe osteopenia (7).
On the other hand, it is known that GH has a paracrine 
effect on bone, besides the well-known endocrine ac-
tion (21). However, only a few papers have evaluated 
whether IGF-I could have a local effect on bone. It can 
be thought that if IGF-I is the GH mediator, IGF-I, local-
ly applied, could have a beneficial effect on bone, like 
GH does (22). As IGF-I has not been yet used locally 
to improve the osseointegration process in osteoporotic 
rabbits, the objective of this study was to assess wheth-
er the local administration of IGF-I could enhance the 
osseointegration process in this osteoporotic animal 
model.
Material and Methods
In the present study, a total of 16 six-month-old female 
New Zealand rabbits were used. This study was ap-
proved by the Local Committee of Ethics for the Use 
of Animals of the Complutense University of Madrid 
(UCM). 
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-Experimental osteoporosis 
A total of 16 rabbits were randomly distributed into two 
groups: a first group with eight animals, that were ovari-
ectomized (ovx) and fed a low-calcium diet for 6 weeks, 
to induce experimental osteoporosis by the method pre-
viously described (OVX) (23). The rest of animals were 
sham-operated and fed a standard diet (HEALTHY).
-Implants insertion 
A total of 32 implants were placed into the rabbit tibiae. 
The implants were screw-type and manufactured from 
commercially pure titanium, 6 mm in length, and 3.3 
mm in diameter, with an external hexagon (B&W®).
Under general anesthesia, titanium monocortical im-
plants, were placed in the proximal part of the anterior 
aspect of the tibia, one centimeter below the anterior 
tibial tuberosity, in its middle face. One implant was 
placed in the left tibia and another one in the right 
tibia. In six of the rabbits (three HEALTHY and three 
OVX), implants were placed without another additional 
substance, and they were considered as controls (CON-
TROL/OVX and CONTROL/HEALTHY). In the other 
ten animals (five HEALTHY and five OVX) implants 
were placed with previous addition of 4 µg of IGF-I into 
the surgical site (GroPep. Thebarton. Australia) (IGF-I/
HEALTHY and IGF-I/OVX). 
In the preoperative period, the surgical field was shaved 
and disinfected with iodine povidone. The rabbits were 
anesthetized with Midazolam (Dormicum, Roche), Ket-
amine Hydrocloride (Imalgene 1000 Merial Laboratorio 
S.A. Barcelona) and Xylazine (Rompún 2% BAYER S.A. 
Barcelona). A full thickness flap was made with muco-
periosteal detachment and the implant site was prepared 
with the drills of the system at low speed (800 rpm) with 
saline solution irrigation. The implants were placed, 
and in the selected animals, 4 µg of IGF-I was applied 
before implants placement. Finally, the surgical wound 
was sutured by planes using 4/0 resorbable Vicryl suture. 
Postoperative antibiotic (oxytetracycline) and analgesic 
(buprenorfine) treatment was administered for five days.
-Histologic processing
Two weeks after implants placement, the animals were 
sacrificed with IV lethal sodium pentobarbital. Soft 
tissue was removed from the tibias and fixed in 10% 
formaldehyde in a buffered solution at pH 7. Samples 
were included in 2-hydroxyethylmethacrylate (Tech-
novit 7200, Heraeus Kulzer, Germany) in growing 
concentrations for two months, following the method 
previously described (23). After polymerization, a ho-
mogeneous block of 20 mm was achieved. Transversal 
cuts were made by the Exakt cutting band microtome 
(Exakt Apparatebau. Norderstedt, Germany). Each sec-
tion was grinded until a final thickness of 50-80 µm 
was obtained. The samples were stained by Masson ś, 
Toluidine Blue, Hematoxylin-Eosin, and were observed 
under light microcopy (Leica). 
-Histomorphometric analysis
The morphometric study was performed by the MIP-
45 imaging analyzer (Digital Image, Barcelona, Spain). 
Measurements of bone-to-implant contact (BIC) ± SD 
(standard deviation) were calculated. BIC was defined 
as the length of bone surface in direct contact with the 
implant perimeter x 100. BIC was measured following 
the method previously described (23). 
Bone Area Density (BAD) analysis was also performed 
in order to measure the newly formed bone in the peri-
implant area. It was calculated as the quotient of bone 
area between threads and the total area between threads 
multiplied in turn by 100.
All the measurements were made by a unique observer.
-Statistical analysis
For statistical analysis, SPSS 22.0 software was used. In 
order to assess the normality assumption of the sample, 
Shapiro Wilk test was applied. Paired test was applied 
to compare between the right and left tibiae data. Anal-
ysis of the variance (ANOVA test) for two factors was 
applied taking as the dependent variable the BIC or the 
BAD value, and as factors OVX and IGF-I. p<0.05 was 
considered to be significant. 
Results
-Histological analysis
In CONTROL/HEALTHY group, newly bone forma-
tion around the implant can be observed. Newly formed 
trabeculae from the periosteum and the endosteum at 
the cortical level can be seen. Neo-formed un-mineral-
ized osteoid tissue at the medullar level can be distin-
guished.
In CONTROL/OVX group, lesser neo-forming activity 
than in the healthy group and greater presence of un-
mineralized osteoid tissue at the compact bone cortex 
can be observed. Lesser presence of neo-formed tra-
beculae from the endosteum can be seen 
In IGF-I/HEALTHY group, histological characteristics 
similar to controls can be seen but with a less dense, 
shorter and thinner trabeculae than in the control group.
In IGF-I/OVX group, short and thin trabeculae can be 
observed. Limited bone activity is observed as well as 
slightly neo-formation of trabeculae and osteoid tissue 
is shown (Fig. 1) 
-Morphometrical Analysis
Bone to implant contact (BIC) and Bone Area Density 
(BAD) means ± SD were obtained by the MIP-45 im-
aging analyzer. The paired test showed no differences 
between left and right tibiae data, so all of them were 
considered for the statistical analysis. Shapiro Wilk test 
showed normality of the sample, so ANOVA test was 
performed. 
Lower values of BIC in the OVX group respect to the 
HEALTHY group were observed, but this difference, 
was not statistically significant. However, in terms of 
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Fig. 1: Comparison of the four study groups. Toluidine blue staining. A) CONTROL/HEALTHY group. B) CON-
TROL/OVX group. C) IGF-I/HEALTHY group. D) IGF-I/OVX group.
BAD, statistically significant differences were found 
when OVX and HEALTHY groups were compared 
(p=0.008). 
No significant differences were detected neither on the 
BIC nor on BAD with local IGF-I administration. Like-






















growth factor were seen, although without statistically 
significance (Figs. 2,3).
Discussion
Therapies against osteoporosis are antiresorptive or an-
abolic drugs. Bisphosphonates (BPs) are included into 
Fig. 2: BIC values.

























Fig. 3: BAD values.
the first group, and teriparatide (1-34 PTH) belongs to 
the second one (9). However, in the recent years several 
novel anti-osteoporosis drugs have been developed, such 
as monoclonal antibodies against RANKL (Denosumab-
Prolia®), or against sclerostin (a novel protein secreted 
by osteocytes which is a negative regulator of bone for-
mation) (Blosozumab and Romosozumab, not allowed by 
FDA yet) (24). Their commercial availability is expected 
by 2020, since clinical trial are providing good results 
(25). Denosumab data indicate good results in increasing 
bone mass in osteoporotic patients, although adverse ef-
fects in the jaws have been registered, similarly than BPs 
(26). However, the prevalence of these side effects is mi-
nor with Denosumab than BPs, and they seem to revert 
when Denosumab withdrawal is carried out. 
Due to current anti-osteoporotic drugs have been re-
ported to have adverse effects, other anabolic substanc-
es such as GH and IGF-I have been studied for bone 
loss-related diseases treatment (9, 27).
To our knowledge, this is the first study in which the 
effect of locally applied IGF-I on the osseointegration 
process in osteoporotic rabbits is evaluated.
The experimental osteoporosis model for the implant 
placement has been already validated by our group 
(28). This experimental animal model was obtained by 
a bilateral OVX and a low-calcium diet of 0.07% of cal-
cium, instead of 0.14% in the standard diet, for 6 weeks. 
After this time a decrease in BMD of 4-10% was ob-
tained depending on the studied area (calotte, tibia or 
cervical spine). This is the model the authors used in 
this current study.
-Osteoporosis and osseointegration
Several authors have studied the osseointegration char-
acteristics in osteoporotic bone. The literature shows 
that induced osteoporosis in animals produces an altera-
tion on the osseointegration process and a significant re-
duction in the BIC values. Thus, Lugero and colleagues 
(2000) (29) studied the osseointegration of two types of 
implants (threaded and cylindrical) in osteoporotic rab-
bits. The authors reported that bone formation is greater 
in the control group but, although osteoporosis affects 
the healing of bone tissue around the implant, pro-
longing the process, osseointegration can be achieved 
in osteoporotic bone. Duarte and collaborators (2008) 
(30) evaluated the influence of estrogen deficiency on 
the bone around implants in ovariectomized rats. The 
authors observed significant lower trabecular values in 
ovx rats versus controls.
However, despite considering osteoporosis as a pos-
sible contraindication for implants placement, there are 
several histological studies in humans in which implant 
osseointegration has been evaluated, obtaining high 
percentages of bone-to-implant surface that confirm the 
presence of osseointegration as well as the presence of 
healthy bone in intimate contact with implants surface 
(31,32), although the general recommendations are lon-
ger healing times in osteoporotic patients (10).
-IGF-I and osseointegration
Regarding the possible influence of IGF-I on the osseo-
integration process, animal experimentation has dem-
onstrated the anabolic role of IGF-I on BMD, verifying 
a decrease in BMD if the IGF-I production or function 
is altered, and an increase in bone mass if exposure to 
IGF-I is increased (12,33). 
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However, clinical trials have shown that at low-doses, 
IGF-I increases bone formation, and at high doses, it in-
creases bone remodeling in women with osteopenia due 
to anorexia nervosa (34). Although the function of IGF-I 
in the process of bone resorption is unclear, it is known 
that IGF-I induces the synthesis of RANKL and, subse-
quently, enhances osteoclastogenesis, increasing bone 
resorption (35). Thus, IGF-I activates the bone remodel-
ing process as GH does (14). 
A few studies combine different growth factors with 
IGF-I. Accordingly, Lynch and colleagues (1989) (36) 
were the first group to evaluate the osseointegration pro-
cess after local administration of IGF-I+PDGF (Platelet 
Derived Growth Factor) prior to the implant insertion in 
dogs. At seven days, the percentage of implant surface 
in contact with the new bone was evaluated, being the 
data statistically significant.
The same combination of growth factors was used by 
Stefani et al (2000) (37), who analyzed the osseointe-
gration process at 3, 8 and 12 weeks. In their study, BIC 
values were proved to be greater at 3 weeks, rather than 
at 12 weeks, showing the beneficial effect of the com-
bination of IGF-I+PDGF on the initial phase of the os-
seointegration process.
Similar results were demonstrated by Nociti and co-
workers (2000) (38). In this study the application of 
PDGF in combination with IGF-I simultaneously with 
implants placement, showed a significantly higher BIC 
value and a greater percentage of bone area when com-
pared with the controls.
IGF-I, osseointegration and osteoporosis
This is the first study which evaluates the influence of 
the local application of IGF-I on osseointegration in 
osteoporotic rabbits. In 2017, Xing and colleagues (39) 
published a study that evaluate the influence of IGF-I 
on titanium implants coated by layer-by-layer polyelec-
trolyte multilayers, under osteoporotic conditions. They 
concluded that the application of IGF-I could promote 
osseointegration in osteoporotic animals, since the local 
application of IGF-I seems to promote early adhesion of 
bone marrow mesenchymal stem cells as well as their 
differentiation. At eight weeks, the histological analysis 
showed greater bone-to-implant contact in test versus 
controls.
Our group was the first to demonstrate the effect of GH 
locally applied on the peri-implant bone reaction in an 
experimental animal model, both under osteoporotic 
conditions (22) and without osteoporosis (40, 41), ob-
taining an improvement in peri-implant osteogenesis 
and higher BIC, 15 days after implant placement, with 
local GH treatment.
Considering that IGF-I is the GH mediator, it is conceiv-
able that local administration of IGF-I could have a GH-
like effect. However, in this current study, local admin-
istration of 4 µg of IGF-I did not induce any histological 
changes, neither on the BIC or BAD in OVX animals, 
nor in animals without osteoporosis, suggesting that the 
4 µg dose may be very small compared to the 4 IU of 
GH (equivalent to 1.3 mg of GH).  
Regarding animals without osteoporosis, the applica-
tion of IGF-I decreased BIC values, although without 
statistically significance. This could be due to the fact 
that IGF-I is able to accelerate the remodeling process 
(7) and, after 15 days, the resorptive phase could pre-
dominate over apposition. On the other hand, because 
the half-life of IGF-I is only three hours, it could be as-
sumed that if its administration had been carried out by 
a continuous infusion pump or by encapsulation, which 
allow a sustained release, greater differences could have 
been obtained (42, 43).
Conclusions
In spite of the beneficial effects reported by other au-
thors, and within the limitations of this experimental 
study, it can be concluded that local administration of 4 
µg of IGF-I is not able to enhance the osseointegration 
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